WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407227
Description: BMS-351 is a potent and selective, nonsteroidal CYP17A1 lyase inhibitor with robust selectivity over steroidogenic CYPs 21A2 and 11B1. BMS-351 emerges as an outstanding preclinical candidate to treat CRPC and is likely to minimize the side effects of current therapies due to its exceptional selectivity. BMS-351 is potentially useful for the Treatment of Prostate Cancer.
MedKoo Cat#: 407227
Chemical Formula: C15H12F3N3
Exact Mass: 291.0983
Molecular Weight: 291.28
Elemental Analysis: C, 61.85; H, 4.15; F, 19.57; N, 14.43
Synonym: BMS-351; BMS 351; BMS351.
IUPAC/Chemical Name: 4-(4-methylpyridin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazole
InChi Key: OFFVLUDFSIUVMI-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H12F3N3/c1-10-5-6-19-7-12(10)11-3-2-4-13-14(11)20-9-21(13)8-15(16,17)18/h2-7,9H,8H2,1H3
SMILES Code: FC(F)(F)CN1C2=CC=CC(C3=C(C)C=CN=C3)=C2N=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 291.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
Audris Huang, Lata Jayaraman, Aberra Fura, Gregory D. Vite, George L. Trainor, Marco M. Gottardis, Thomas E. Spires, Vanessa M. Spires, Cheryl A. Rizzo, Mary T. Obermeier, Paul A. Elzinga, Gordon Todderud, Yi Fan, John A. Newitt, Sophie M. Beyer, Yongxin Zhu, Bethanne M. Warrack, Angela K. Goodenough, Andrew J. Tebben, Arthur M. Doweyko, David L. Gold, and Aaron Balog. Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer. ACS Med. Chem. Lett. Articles ASAP (As Soon As Publishable); Publication Date (Web): December 2, 2015 (Letter); DOI: 10.1021/acsmedchemlett.5b00310